A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

NCT02328261 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: Icotinib

Sponsor

Betta Pharmaceuticals Co., Ltd.